Symbols

BLLN

BillionToOne·NASDAQ

--(--)

BLLN Profile

Billiontoone, Inc.

A high-growth U.S.molecular diagnostics company,specializing in single-base-pair precision DNA detection technology,primarily focused on non-invasive prenatal testing and cancer liquid biopsy products

Industry

Biological Technology

Established Date

Listing Date

11/06/2025

Exchange

NASDAQ Stock Exchange

Full-time Employees

713

Fiscal Year Ends

12-31

Website

www.billiontoone.com

Security Type

Common stock

Office address

1035 O’Brien Drive Menlo Park CA 94025

Business

Introduction

BillionToOne, Inc., began operations as a Delaware corporation in 2016. The company has developed a revolutionary single-molecule next-generation sequencing (smNGS) platform capable of detecting and precisely quantifying gene targets with single-molecule sensitivity. At the heart of this innovation is its patented Quantitative Counting Template (QCT), which measures at the level of a single DNA molecule. This technology breaks through a key bottleneck in healthcare in detecting sparse but clinically significant disease signals in free DNA. BillionToOne's technology platform has been successfully applied to a range of groundbreaking prenatal and oncology products that provide actionable diagnostic information with only a simple blood sample.